Digital Therapeutics for Neurological Disorders Market Size to Reach USD 504.36 Million by 2033 as Prescription Neuro-DTx, Insomnia Care Apps, and Software-Based Cognitive Treatments Gain Momentum

April 19, 2026 - The global Digital Therapeutics for Neurological Disorders Market reached USD 246.94 million in 2024 and is expected to reach USD 504.36 million by 2033, growing at a CAGR of 8.3% during 2025-2033, based on the market data provided. The market is expanding as software-based interventions move deeper into neurology, sleep medicine, behavioral health, and cognitive care, giving providers new ways to address attention disorders, insomnia, migraine, epilepsy-adjacent monitoring, and other neurological conditions through clinically validated digital programs. DataM Intelligence lists this as a dedicated neurological digital therapeutics category and notes regional expansion across North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Request Updated Sample Report: https://www.datamintelligence.com/download-sample/digital-therapeutics-for-neurological-disorders-market?kailas

Growth is being supported by stronger regulatory familiarity with software as a medical device, wider acceptance of prescription digital therapeutics, and increasing demand for scalable non-drug or adjunctive treatments that can be delivered through mobile apps and connected platforms. The broader digital therapeutics market reached USD 6.84 billion in 2024, with software accounting for 45.5% share and North America accounting for 43.3% share, which provides a useful directional benchmark for this neurological submarket.

Recent Developments

Recent market activity shows that neurological digital therapeutics are moving beyond narrow pilots into better-funded and more commercially structured platforms. In April 2025, the FDA granted marketing authorization to Click Therapeutics' CT-132, described by DataM Intelligence as the first prescription digital therapeutic authorized in the U.S. for the preventive treatment of episodic migraine. That milestone is especially important for this market because migraine sits squarely within neurological care and demonstrates regulatory acceptance of software-led neurological treatment.

In April 2026, Click Therapeutics and Boehringer Ingelheim announced new Series D funding to advance commercialization of CT-155 and scale Click's software-as-treatment platform. The companies said Click's digital therapeutics pipeline spans indications including neurology, reinforcing the sector's continued investment momentum.

In February 2026, Big Health announced USD 23.7 million in new funding to accelerate adoption of SleepioRx and DaylightRx. Big Health says SleepioRx is an FDA-cleared digital treatment for insomnia disorder, a meaningful point for this market because insomnia is one of the most commercially relevant neurological-adjacent disease pathways in digital therapeutics.

Akili also remains a visible player in neurological digital therapeutics. Its official site continues to position the company as a prescription digital medicine developer, and its product pages say EndeavorRx and EndeavorOTC use adaptive sensory and motor challenges to target attentional control through software-based treatment experiences.

Segment Analysis
By Product Type: Software Therapeutics

Software is likely the largest product-type segment in this market because neurological digital therapeutics are primarily delivered through regulated mobile applications, prescription software, and app-based cognitive or behavioral treatment programs rather than hardware-heavy systems. In the broader digital therapeutics market, software held 45.5% share in 2024. Applying that share directionally to your 2024 neurological DTx market size of USD 246.94 million implies an estimated software segment value of about USD 112.4 million. I'm treating this as a directional estimate because the share comes from the broader DTx market, not this exact neurological-only subset.

By Disease Type: Insomnia and Sleep-Related Neurological Disorders

Insomnia and sleep-related disorders appear to be one of the most commercially mature disease segments because they already have FDA-cleared digital treatment pathways and reimbursement traction. A public market summary values the digital insomnia therapeutics market at USD 2.1 billion in 2024, showing that software-delivered sleep treatment is already a sizable standalone opportunity. Big Health's FDA-cleared SleepioRx further supports the view that sleep-related neurological conditions are among the most commercially advanced segments within neurological digital therapeutics. Because your provided segmentation table does not specify disease subshares, I am presenting insomnia as a leading commercial segment on a directional basis rather than assigning an exact percentage of your market total.

Market Segmentation

The Digital Therapeutics for Neurological Disorders Market is segmented by Product Type, Disease Type, End-User, and Region. Regionally, the market spans North America, Latin America, Europe, and Asia Pacific in your supplied structure, while the DataM Intelligence market page also lists broader coverage including the Middle East and Africa. Key companies named for the market include Akili, Click Therapeutics, Big Health, Apple, MindMaze, NeuroPace, NeurologyToolKit, Matoph Labs, Fullpower Technologies, and Neybox Digital.

Regional Analysis
United States

The United States remains the most important national market for neurological digital therapeutics because of its large digital-health spending base, FDA-led regulatory pathways for software as a medical device, and early commercialization of prescription digital therapies for ADHD, insomnia, and migraine. The broader U.S. digital therapeutics market reached USD 2,183.0 million in 2025 and is projected to reach USD 16,228.3 million by 2034 at a 23.47% CAGR. Relative to the neurological DTx market value you supplied, this indicates that the U.S. is the leading commercialization environment, even though the country number is for the broader DTx market rather than only neurological disorders.

U.S. growth trends are being supported by FDA familiarity with digital health products and by commercialization of neurological and behavioral software treatments such as Click's migraine therapy and Big Health's insomnia treatment. The FDA's Digital Health Center of Excellence says it is working to advance responsible digital health innovation, and FDA guidance pages continue to maintain a defined framework for digital health and software-based medical products. That regulatory clarity materially supports market development in the U.S.

Japan

Japan is emerging as an important Asia-Pacific market because of its aging population, growing acceptance of software as a medical device, and clearer pathways for therapeutic apps. The Japan digital therapeutics market reached USD 384.8 million in 2025 and is projected to reach USD 2,019.2 million by 2034 at a 20.23% CAGR. Relative to your neurological DTx dataset, that suggests Japan is one of the more attractive regional opportunities, though the figure again refers to the broader DTx market rather than only neurological disorders.

Japan's policy impact is meaningful. PMDA's 2025 update notes that the Japan market for therapeutic SaMD is projected to reach USD 918 million by 2027, and it highlights government efforts from MHLW and METI to support software-as-a-medical-device development. Independent Japanese industry analysis also notes that Japan has formalized review and reimbursement pathways for DTx products, including earlier reimbursement for therapeutic apps. Together, those factors create a supportive policy backdrop for neurological digital therapeutics.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=digital-therapeutics-for-neurological-disorders-market?kailas

Company Profiles
Akili

Akili is one of the most recognizable neurological digital therapeutics companies because it focuses on prescription digital medicine built around cognitive neuroscience. Its official site says the company is a prescription digital medicine company, and its product pages describe EndeavorRx and EndeavorOTC as software products that deliver adaptive sensory and motor stimuli to target attentional control. That gives Akili a strong position in software-led neurological intervention, especially in attention-related disorders.

Click Therapeutics

Click Therapeutics is a major platform player in neurological DTx. Its official site says the company develops regulated, clinically validated digital treatments and operates at the intersection of neuroscience and software. Recent company and partner announcements also show momentum in neurology, including financing tied to CT-155 and prior U.S. authorization of CT-132 for episodic migraine prevention. That positions Click as one of the most commercially advanced software-treatment companies in neurological care.

NeuroPace

NeuroPace brings a different but highly relevant neurological technology profile to the market through neurotechnology and connected therapy for epilepsy. Its investor relations site says the company reported full-year 2025 financial results and continues to guide 2026 performance, reflecting an established commercial platform in neurology. While NeuroPace is more device-centered than pure-play app-based DTx vendors, its presence in the company set is important because neurological digital care is increasingly blending software, remote data, and therapy optimization.

Analyst View

The Digital Therapeutics for Neurological Disorders Market is evolving from early proof-of-concept into a more structured software-therapy segment anchored by prescription digital products, sleep-related neurological care, and regulatory-cleared migraine and attention treatments. The strongest current commercial opportunities appear to be in software-first platforms and in disease areas where clinical workflow fit is already visible, especially insomnia, migraine, and attention-related disorders. The United States remains the clearest scale market because of FDA activity and commercialization depth, while Japan is becoming more attractive because therapeutic SaMD policy and reimbursement pathways are maturing. Vendors that can combine clinical validation, regulatory execution, and scalable software delivery are likely to capture the greatest share of growth as the market advances toward USD 504.36 million by 2033.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.